CoChat

Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series

Open access

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Following recent approval of pirfenidone and nintedanib for idiopathic pulmonary fibrosis (IPF), questions arise about the use of these antifibrotics in patients awaiting lung transplantation (LTx). METHODS: Safety and efficacy of antifibrotic drugs in IPF patients undergoing LTx were investigated in a single-centre retrospective cohort analysis. RESULTS: A total of nine patients, receiving antifibrotic therapy for 419 ± 315 days until subsequent LTx, were included. No major side effects were noted. Significant weight loss occurred during antifibrotic treatment (p = 0.0062). FVC tended to stabilize after 12 weeks of treatment in most patients. A moderate decline in FVC, TLC and DLCO was noted during the whole pretransplant time period of antifibrotic therapy. Functional exercise capacity and lung allocation score remained unchanged. No post-operative thoracic wound healing problems, nor severe early anastomotic airway complications were attributable to prior antifibrotic treatment. None of the patients developed chronic lung allograft dysfunction after a median follow-up of 19.8 (11.2-26.5) months; and post-transplant survival was 100% after 1 year and 80% after 2 years. CONCLUSIONS: Antifibrotic drugs can probably be safely administered in IPF patients, possibly attenuating disease progression over time, while awaiting LTx.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12890-016-0308-z

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Forced Vital Capacity in IPF patients with at least 6 months antifibrotic therapy before transplantation. Forced Vital Capacity (FVC) (%predicted) is given at the start of antifibrotic therapy (start), 3 months before and respectively 3, 6, 9 and 12 months (mo) after start. Dotted lines connect values in patients (n = 6/9) with consecutive measurements at different time points; p-values (Wilcoxon signed rank test) above each time point are given compared to start; or compared another time point (time-frame indicated by full line)
Fig. 1 Forced Vital Capacity in IPF patients with at least 6 months antifibrotic therapy before transplantation. Forced Vital Capacity (FVC) (%predicted) is given at the start of antifibrotic therapy (start), 3 months before and respectively 3, 6, 9 and 12 months (mo) after start. Dotted lines connect values in patients (n = 6/9) with consecutive measurements at different time points; p-values (Wilcoxon signed rank test) above each time point are given compared to start; or compared another time point (time-frame indicated by full line)CC BY · PubMed Central
Fig. 2 Pretransplant evolution of pulmonary function and functional exercise capacity following treatment with antifibrotic drugs. Forced Vital Capacity (FVC) (a), Total Lung Capacity (TLC) (b), Diffusion capacity (DLCO) (c) (all in (%predicted) and 6 min walk test (6MWT, meter) (d) at start of antifibrotic therapy (start) and at the moment of lung transplantation (LTx) in the included IPF patients. Dotted lines connect values in patients (n = 6/9) with a consecutive measurement at six months and just before transplantation; p-values (Wilcoxon signed rank test) are given for patients that had consecutive measurements
Fig. 2 Pretransplant evolution of pulmonary function and functional exercise capacity following treatment with antifibrotic drugs. Forced Vital Capacity (FVC) (a), Total Lung Capacity (TLC) (b), Diffusion capacity (DLCO) (c) (all in (%predicted) and 6 min walk test (6MWT, meter) (d) at start of antifibrotic therapy (start) and at the moment of lung transplantation (LTx) in the included IPF patients. Dotted lines connect values in patients (n = 6/9) with a consecutive measurement at six months and just before transplantation; p-values (Wilcoxon signed rank test) are given for patients that had consecutive measurementsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 1

  1. National Clinical Guideline Centre (UK). Diagnosis and management of suspected idiopathic pulmonary fibrosis: idiopathic pulmonary fibrosis, National Institute for Health and Care Excellence: clinical guidelines. London: Royal College of Physicians (UK); 2013.

Cited by

See all 67

Metadata

Authors
Delanote, I., Wuyts, W. A., Yserbyt, J., Verbeken, E. K., Verleden, G. M., & Vos, R.
Affiliations
  • Universitair Ziekenhuis Leuven (BE)
  • KU Leuven (BE)
Corresponding author
Vos, Robin
Venue
BMC Pulmonary Medicine
Published
2016-11-18
Volume
16
Issue
1
Pages
156-156
ISSN
1471-2466 (ISSN-L)
OpenAlex
W2550940244
Cited by
65
References
19
Citations by year
2025: 1 · 2024: 1 · 2023: 8 · 2022: 6 · 2021: 9 · 2020: 3 · 2019: 6 · 2018: 13 · 2017: 18
FWCI
11.02
Type
journal article
Language
en
Open access
Locations
  • BMC Pulmonary Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion, cc-by)
Funders
  • Fonds Wetenschappelijk Onderzoek (12G8715N, .0723.10, G.0679.12 and G.0679.12)
  • Universitaire Ziekenhuizen Leuven (STG/15/023)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
idiopathic pulmonary fibrosis, lung transplantation, antifibrotic agents, pirfenidone, nintedanib, drug safety, forced vital capacity decline, weight loss, chronic lung allograft dysfunction, post-transplant survival, lung allocation score
MeSH terms
Aged, Anti-Inflammatory Agents, Non-Steroidal, Belgium, Female, Graft Survival, Humans, Indoles, Lung, Male, Middle Aged, Postoperative Complications, Pyridones, Retrospective Studies, Vital Capacity, Lung Transplantation, Disease Progression, Idiopathic Pulmonary Fibrosis, Tertiary Care Centers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. https://app.cochat.ai/papers/10.1186/s12890-016-0308-z
The paper
Delanote, I., Wuyts, W. A., Yserbyt, J., Verbeken, E. K., Verleden, G. M., & Vos, R. (2016). Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC Pulmonary Medicine. https://doi.org/10.1186/s12890-016-0308-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.